Discovery of GLP-1–Based Drugs for the Treatment of Obesity
WEB2 days ago · 215.13 KB. The 2024 Lasker–DeBakey Clinical Medical Research Award recognizes Drs. Habener, Mojsov, and Knudsen, who developed GLP-1 medicines that have revolutionized the treatment of obesity.
Research That Led to Obesity Drugs Wins Major Medical Prize
WEB3 days ago · Novo Nordisk scientists then developed GLP-1 analogs that lasted a week, which led to the semaglutide, or the diabetes drug Ozempic. It was followed by Wegovy, for obesity, which caused an average ...
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive …
WEBJun 21, 2023 · GLP-1 agonists, used to treat type 2 diabetes, have been shown to be effective in promoting weight loss in preclinical and clinical studies. This review summarizes numerous studies conducted on the main drugs in the GLP-1 agonists class, outlining the maximum achievable weight loss.
Beyond Ozempic: New GLP-1 drugs promise weight loss and …
WEBThe next wave of obesity drugs is coming soon. Drug companies are racing to develop GLP-1 drugs following the blockbuster success of Novo Nordisk’s Ozempic and Wegovy and Eli...
What is the pipeline for future medications for obesity?
WEBFeb 1, 2024 · Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15–17% mean weight loss (WL) with evidence of cardioprotection.
GLP-1 physiology in obesity and development of incretin-based drugs …
WEBAug 19, 2024 · I provide details regarding the development of GLP-1 receptor agonists for anti-obesity therapy and discuss the possible mechanism behind their beneficial effects on adverse...
GLP−1 receptor agonists for the treatment of obesity: Role as a ...
WEBFeb 1, 2023 · GLP-1R agonists improve glucose homeostasis in patients with T2DM, cause weight loss, and benefit cardiovascular health over time. However, dose-dependent gastrointestinal effects limit efficacy, so drugs with GLP-1 and GCG pharmacology can also target alternative pathways and may expand the therapeutic index .
Obesity-drug pioneers win prestigious Lasker Award for medical …
WEB3 days ago · GLP-1-based drugs don’t just treat obesity and diabetes. Studies have shown they can help with cardiovascular disease, sleep apnea and kidney disease, among other conditions.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
WEBFeb 10, 2021 · Liraglutide administered subcutaneously once daily is the only GLP-1 receptor agonist approved for weight management. 3,19,34 Our trial showed greater mean placebo-corrected weight reductions...
Winning researchers unlocked GLP-1 drugs for obesity | Science
WEBMay 30, 2024 · In 2023, Science named the development of GLP-1 agonists to treat obesity—and their efficacy at blunting obesity-associated health problems—as its latest Breakthrough. To select the winners, Science journals’ editor-in-chief, Holden Thorp, convened a committee.
- Some results have been removed
Skip to content